Published in Drug Discov Today on February 27, 2013
Serial femtosecond crystallography of G protein-coupled receptors. Science (2013) 3.58
Kinetics of protein-ligand unbinding: Predicting pathways, rates, and rate-limiting steps. Proc Natl Acad Sci U S A (2015) 1.17
A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA. ACS Chem Biol (2014) 1.00
Role of water and steric constraints in the kinetics of cavity-ligand unbinding. Proc Natl Acad Sci U S A (2015) 0.93
Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1. Sci Rep (2015) 0.82
Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov (2016) 0.81
Enhanced, targeted sampling of high-dimensional free-energy landscapes using variationally enhanced sampling, with an application to chignolin. Proc Natl Acad Sci U S A (2016) 0.80
Asynchronous Replica Exchange Software for Grid and Heterogeneous Computing. Comput Phys Commun (2015) 0.79
Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors. Br J Pharmacol (2014) 0.77
Molecular insights into the dynamics of pharmacogenetically important N-terminal variants of the human β2-adrenergic receptor. PLoS Comput Biol (2014) 0.77
Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. J Biol Chem (2015) 0.76
Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol (2015) 0.76
Multiple Ligand Unbinding Pathways and Ligand-Induced Destabilization Revealed by WExplore. Biophys J (2017) 0.75
Measurement of Ligand-Target Residence Times by (1)H Relaxation Dispersion NMR Spectroscopy. J Med Chem (2016) 0.75
Cheminformatics Research at the Unilever Centre for Molecular Science Informatics Cambridge. Mol Inform (2015) 0.75
How wet should be the reaction coordinate for ligand unbinding? J Chem Phys (2016) 0.75
Enhanced potency of bivalent small molecule gp41 inhibitors. Bioorg Med Chem (2016) 0.75
Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting. Sci Rep (2016) 0.75
As Simple As Possible, but Not Simpler: Exploring the Fidelity of Coarse-Grained Protein Models for Simulated Force Spectroscopy. PLoS Comput Biol (2016) 0.75
Cinnamide Derivatives of d-Mannose as Inhibitors of the Bacterial Virulence Factor LecB from Pseudomonas aeruginosa. ChemistryOpen (2015) 0.75
Thermodynamics of protein-ligand interactions as a reference for computational analysis: how to assess accuracy, reliability and relevance of experimental data. J Comput Aided Mol Des (2015) 0.75
Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells. Front Immunol (2017) 0.75
SEEKR: Simulation Enabled Estimation of Kinetic Rates, A Computational Tool to Estimate Molecular Kinetics and Its Application to Trypsin-Benzamidine Binding. J Phys Chem B (2017) 0.75
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem (2004) 15.51
Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins (2010) 9.43
Atomic-level characterization of the structural dynamics of proteins. Science (2010) 8.36
How fast-folding proteins fold. Science (2011) 6.24
Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature (2011) 5.35
A hierarchical approach to all-atom protein loop prediction. Proteins (2004) 5.18
The dynamic process of β(2)-adrenergic receptor activation. Cell (2013) 4.09
Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83
Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struct Biol (2009) 3.81
Mechanism of voltage gating in potassium channels. Science (2012) 3.24
How robust are protein folding simulations with respect to force field parameterization? Biophys J (2011) 3.00
Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys (2012) 2.85
Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. Proc Natl Acad Sci U S A (2009) 2.77
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell (2012) 2.67
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Activation mechanism of the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2011) 2.53
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des (2006) 2.53
Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell (2013) 2.49
Principles of conduction and hydrophobic gating in K+ channels. Proc Natl Acad Sci U S A (2010) 2.47
Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A (2011) 2.44
High-resolution crystal structure of human protease-activated receptor 1. Nature (2012) 2.44
Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. J Chem Phys (2005) 2.32
Architecture and membrane interactions of the EGF receptor. Cell (2013) 2.29
Systematic validation of protein force fields against experimental data. PLoS One (2012) 2.29
A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A (2008) 2.18
Real-world illumination and the perception of surface reflectance properties. J Vis (2003) 2.17
How does a drug molecule find its target binding site? J Am Chem Soc (2011) 2.13
Microsecond molecular dynamics simulation shows effect of slow loop dynamics on backbone amide order parameters of proteins. J Phys Chem B (2008) 1.90
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Mechanism of Na+/H+ antiporting. Science (2007) 1.79
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
Atomic-level description of ubiquitin folding. Proc Natl Acad Sci U S A (2013) 1.65
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature (2013) 1.59
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci U S A (2008) 1.58
Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res (2006) 1.58
Refinement of protein structure homology models via long, all-atom molecular dynamics simulations. Proteins (2012) 1.52
The role of ligands on the equilibria between functional states of a G protein-coupled receptor. J Am Chem Soc (2013) 1.48
Computational design and experimental testing of the fastest-folding β-sheet protein. J Mol Biol (2010) 1.46
Structure and dynamics of an unfolded protein examined by molecular dynamics simulation. J Am Chem Soc (2012) 1.46
Protein folding kinetics and thermodynamics from atomistic simulation. Proc Natl Acad Sci U S A (2012) 1.46
Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations. J Gen Physiol (2010) 1.44
Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 a and 1.05 a resolution. J Mol Biol (2002) 1.37
A common, avoidable source of error in molecular dynamics integrators. J Chem Phys (2007) 1.34
Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci U S A (2013) 1.34
Dynamic control of slow water transport by aquaporin 0: implications for hydration and junction stability in the eye lens. Proc Natl Acad Sci U S A (2008) 1.30
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther (2006) 1.29
The midpoint method for parallelization of particle simulations. J Chem Phys (2006) 1.27
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol (2012) 1.25
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol (2008) 1.23
Structure of Mycobacterium tuberculosis FtsZ reveals unexpected, G protein-like conformational switches. J Mol Biol (2004) 1.10
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
The future of molecular dynamics simulations in drug discovery. J Comput Aided Mol Des (2011) 1.06
Atomic-level simulation of current-voltage relationships in single-file ion channels. J Gen Physiol (2013) 1.06
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res (2010) 1.04
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia (2010) 1.03
Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci U S A (2012) 1.02
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem Biol (2011) 0.99
Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure. J Chem Phys (2013) 0.94
Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation. J Med Chem (2007) 0.93
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res (2008) 0.93
Evaluating the effects of cutoffs and treatment of long-range electrostatics in protein folding simulations. PLoS One (2012) 0.92
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett (2005) 0.91
Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost (2004) 0.91
Atomistic description of the folding of a dimeric protein. J Phys Chem B (2013) 0.91
An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. J Mol Biol (2006) 0.90
2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Bioorg Med Chem Lett (2009) 0.88